Literature DB >> 9647302

Longitudinal SPECT study in Alzheimer's disease: relation to apolipoprotein E polymorphism.

M Lehtovirta1, J Kuikka, S Helisalmi, P Hartikainen, A Mannermaa, M Ryynänen, H Soininen.   

Abstract

OBJECTIVES: In mild Alzheimer's disease, SPECT imaging of regional cerebral blood flow has highlighted deficits in the posterior association cortex, and later in the disease process, the deficit spreads to involve the frontal cortex. The sigma4 allele of apolipoprotein E is a risk factor for Alzheimer's disease. The effect of apolipoprotein E polymorphism on cerebral perfusion was studied. The hypothesis was that those patients with Alzheimer's disease who carry the sigma4 allele would have more severe cerebral hypoperfusion.
METHODS: Thirty one patients with Alzheimer's disease and eight age and sex matched control subjects were examined in a three year longitudinal study. Patients with Alzheimer's disease were divided into subgroups according to their number of sigma4 alleles. Regional cerebral blood flow ratios referred to the cerebellum were examined by 99mTc-HMPAO SPECT. Apolipoprotein E genotypes were determined by digestion of polymerase chain reaction products with the restriction enzyme Hha1.
RESULTS: All patients with Alzheimer's disease had bilateral temporoparietal hypoperfusion compared with control subjects. The two sigma4 allele subgroups had the lowest ratios at the baseline assessment in the parietal and occipital cortices, and at the follow up in the temporal, parietal, and occipital cortices. They had the highest reduction in percentage terms in the temporal and occipital cortices compared with the other subgroups. However, the global clinical severity did not differ at the baseline or follow up examinations between the subgroups.
CONCLUSION: Apolipoprotein E polymorphism is involved in the pathogenesis and heterogeneity of Alzheimer's disease as the most severe cerebral hypoperfusion was found in the sigma4 allele subgroups. This might have implications for therapeutic approaches in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9647302      PMCID: PMC2170126          DOI: 10.1136/jnnp.64.6.742

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  41 in total

1.  The apolipoprotein epsilon 4 allele in patients with Alzheimer's disease.

Authors:  R Mayeux; Y Stern; R Ottman; T K Tatemichi; M X Tang; G Maestre; C Ngai; B Tycko; H Ginsberg
Journal:  Ann Neurol       Date:  1993-11       Impact factor: 10.422

2.  Volumetric MRI analysis of the amygdala and the hippocampus in subjects with age-associated memory impairment: correlation to visual and verbal memory.

Authors:  H S Soininen; K Partanen; A Pitkänen; P Vainio; T Hänninen; M Hallikainen; K Koivisto; P J Riekkinen
Journal:  Neurology       Date:  1994-09       Impact factor: 9.910

3.  Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes.

Authors:  M Lehtovirta; M P Laakso; H Soininen; S Helisalmi; A Mannermaa; E L Helkala; K Partanen; M Ryynänen; P Vainio; P Hartikainen
Journal:  Neuroscience       Date:  1995-07       Impact factor: 3.590

Review 4.  Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype.

Authors:  W J Strittmatter; K H Weisgraber; M Goedert; A M Saunders; D Huang; E H Corder; L M Dong; R Jakes; M J Alberts; J R Gilbert
Journal:  Exp Neurol       Date:  1994-02       Impact factor: 5.330

5.  Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease.

Authors:  E K Perry; V Haroutunian; K L Davis; R Levy; P Lantos; S Eagger; M Honavar; A Dean; M Griffiths; I G McKeith
Journal:  Neuroreport       Date:  1994-03-21       Impact factor: 1.837

6.  Lower cognitive performance in normal older adult male twins carrying the apolipoprotein E epsilon 4 allele.

Authors:  T Reed; D Carmelli; G E Swan; J C Breitner; K A Welsh; G P Jarvik; S Deeb; J Auwerx
Journal:  Arch Neurol       Date:  1994-12

7.  Apolipoprotein E polymorphism and Alzheimer's disease in eastern Finland.

Authors:  M Lehtovirta; S Helisalmi; A Mannermaa; H Soininen; K Koivisto; M Ryynänen; P Riekkinen
Journal:  Neurosci Lett       Date:  1995-02-06       Impact factor: 3.046

Review 8.  Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease.

Authors:  J Poirier
Journal:  Trends Neurosci       Date:  1994-12       Impact factor: 13.837

9.  Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease.

Authors:  G W Small; J C Mazziotta; M T Collins; L R Baxter; M E Phelps; M A Mandelkern; A Kaplan; A La Rue; C F Adamson; L Chang
Journal:  JAMA       Date:  1995 Mar 22-29       Impact factor: 56.272

10.  A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein epsilon 4 allele.

Authors:  H Soininen; O Kosunen; S Helisalmi; A Mannermaa; L Paljärvi; S Talasniemi; M Ryynänen; P Riekkinen
Journal:  Neurosci Lett       Date:  1995-03-03       Impact factor: 3.046

View more
  14 in total

Review 1.  A meta-analysis of structural and functional brain imaging in dementia of the Alzheimer's type: a neuroimaging profile.

Authors:  Konstantine K Zakzanis; Simon J Graham; Zachariah Campbell
Journal:  Neuropsychol Rev       Date:  2003-03       Impact factor: 7.444

2.  Progression of cerebral amyloid load is associated with the apolipoprotein E ε4 genotype in Alzheimer's disease.

Authors:  Timo Grimmer; Susanne Tholen; Behrooz H Yousefi; Panagiotis Alexopoulos; Annette Förschler; Hans Förstl; Gjermund Henriksen; William E Klunk; Chester A Mathis; Robert Perneczky; Christian Sorg; Alexander Kurz; Alexander Drzezga
Journal:  Biol Psychiatry       Date:  2010-07-02       Impact factor: 13.382

3.  Cognitive function after major noncardiac surgery, apolipoprotein E4 genotype, and biomarkers of brain injury.

Authors:  David L McDonagh; Joseph P Mathew; Willam D White; Barbara Phillips-Bute; Daniel T Laskowitz; Mihai V Podgoreanu; Mark F Newman
Journal:  Anesthesiology       Date:  2010-04       Impact factor: 7.892

4.  Metabolic interaction between ApoE genotype and onset age in Alzheimer's disease: implications for brain reserve.

Authors:  L Mosconi; K Herholz; I Prohovnik; B Nacmias; M T R De Cristofaro; M Fayyaz; L Bracco; S Sorbi; A Pupi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-01       Impact factor: 10.154

Review 5.  Neuroimaging in Alzheimer's disease: relevance for treatment.

Authors:  C H van Dyck
Journal:  Curr Psychiatry Rep       Date:  2001-02       Impact factor: 5.285

Review 6.  Ketone bodies as a therapeutic for Alzheimer's disease.

Authors:  Samuel T Henderson
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

7.  APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease.

Authors:  S Cosentino; N Scarmeas; E Helzner; M M Glymour; J Brandt; M Albert; D Blacker; Y Stern
Journal:  Neurology       Date:  2008-04-09       Impact factor: 9.910

8.  APOE-dependent PET patterns of brain activation in Alzheimer disease.

Authors:  N Scarmeas; K E Anderson; J Hilton; A Park; C Habeck; J Flynn; B Tycko; Y Stern
Journal:  Neurology       Date:  2004-09-14       Impact factor: 9.910

Review 9.  The role of APOE in cerebrovascular dysfunction.

Authors:  Leon M Tai; Riya Thomas; Felecia M Marottoli; Kevin P Koster; Takahisa Kanekiyo; Alan W J Morris; Guojun Bu
Journal:  Acta Neuropathol       Date:  2016-02-16       Impact factor: 17.088

10.  Brain metabolic decreases related to the dose of the ApoE e4 allele in Alzheimer's disease.

Authors:  L Mosconi; B Nacmias; S Sorbi; M T R De Cristofaro; M Fayazz; A Tedde; L Bracco; K Herholz; A Pupi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-03       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.